{"organizations": [], "uuid": "ce99bdfb6a846d72e8a425f98cd01bea97f8a8c5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180507.html", "section_title": "Archive News &amp; Video for Monday, 07 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-genkyotex-announces-smbs-positive/brief-genkyotex-announces-smbs-positive-review-of-gkt831-phase-2-trial-in-primary-biliary-cholangitis-idUSFWN1SD04P", "country": "US", "domain_rank": 408, "title": "Genkyotex Announces SMB's Positive Review Of GKT831 Phase 2 Trial In Primary Biliary Cholangitis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.278, "site_type": "news", "published": "2018-05-07T13:28:00.000+03:00", "replies_count": 0, "uuid": "ce99bdfb6a846d72e8a425f98cd01bea97f8a8c5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-genkyotex-announces-smbs-positive/brief-genkyotex-announces-smbs-positive-review-of-gkt831-phase-2-trial-in-primary-biliary-cholangitis-idUSFWN1SD04P", "ord_in_thread": 0, "title": "Genkyotex Announces SMB's Positive Review Of GKT831 Phase 2 Trial In Primary Biliary Cholangitis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "genkyotex announces smb", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 7 (Reuters) - GenKyoTex SA:\n* GENKYOTEX ANNOUNCES POSITIVE OUTCOME FROM INDEPENDENT SMB’S FIRST PRE-PLANNED REVIEW OF GKT831’S PHASE 2 TRIAL IN PRIMARY BILIARY CHOLANGITIS\n* RESULTS OF INTERIM EFFICACY ANALYSIS FROM PHASE 2 TRIAL EXPECTED TO BE AVAILABLE IN FALL 2018\n* A TOTAL OF 102 PBC PATIENTS WILL BE ENROLLED AND ALLOCATED TO PLACEBO OR ONE OF TWO DOSES OF GKT831\n* SMB RECOMMENDED CONTINUATION OF STUDY AS PER PROTOCOL, WITH NO CHANGES OR ADDITIONAL DATA COLLECTION REQUIRED Source text for Eikon: (Gdynia Newsroom)\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-07T13:28:00.000+03:00", "crawled": "2018-05-08T16:51:55.000+03:00", "highlightTitle": ""}